Central Nervous System

PV QA 2 - Poster Viewing Q&A 2

MO_7_2630 - Safety profile of tumor treating fields in adult glioblastoma patients with implanted non-programmable shunts, programmable shunts, and pacemakers/defibrillators: 6-year updated retrospective analysis

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Safety profile of tumor treating fields in adult glioblastoma patients with implanted non-programmable shunts, programmable shunts, and pacemakers/defibrillators: 6-year updated retrospective analysis
Y. Kew1, and N. A. Oberheim2; 1Methodist Hospital,, Houston, TX, 2University of California, San Francisco, CA

Purpose/Objective(s): Tumor Treating Fields (TTFields) are a noninvasive, loco-regional, anti-mitotic cancer treatment approved in the U.S. for adults with recurrent and newly diagnosed glioblastoma (GBM). TTFields (low intensity, intermediate frequency, alternating electric fields) are delivered by a portable medical device (Optune®). GBM patients may develop hydrocephalus and benefit from subsequent shunt placement. Safety information on concomitant use of TTFields with implanted devices in GBM patients will identify potential interference with the functioning of these devices.

Materials/Methods: A review of the clinical information for GBM patients treated with TTFields in the U.S. between November 2011 and October 2017 identified 79 patients with non-programmable shunts (NPS), 11 with programmable shunts (PS), and 14 with pacemakers/defibrillators (PM/DF). The safety data obtained from post-market surveillance in all 104 patients were analyzed to identify implantable device-related adverse events.

Results: Adverse events (AEs) reported for these 104 patients did not reveal any new safety concerns on concurrent use of Optune with implanted devices. Infections or infestations (bronchitis, diverticulitis, infection NOS, meningitis, sepsis, shunt infection, upper respiratory and urinary tract infections, wound infection) were reported in 12/79 (15.2%) of NPS patients and in 4/11 (36.4%) of PS patients. No arrhythmia or other cardiac adverse events were reported in the 14 patients with PM/DF. Skin irritations were seen in 5.1% of NPS patients (including 1.3% ulcerations). Neurological symptoms (35.4%), which included convulsions (15.2%) in the NPS patients were related to the underlying tumor rather than TTFields treatment. Hydrocephalus was seen in 6/79 (7.6%) NPS and 2/11(18.2%) PS patients but were not related to shunt malfunction.

Conclusion: No unexpected safety issues were observed in the 104 patients analyzed in this updated report. Further evaluation of the concurrent use of TTFields with programmable shunts and pacemaker/defibrillators should include bench testing of the compatibility of these devices to TTFields.

Author Disclosure: Y. Kew: None. N.A. Oberheim: None.

Send Email for Yvonne Kew


Assets

MO_7_2630 - Safety profile of tumor treating fields in adult glioblastoma patients with implanted non-programmable shunts, programmable shunts, and pacemakers/defibrillators: 6-year updated retrospective analysis



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Safety profile of tumor treating fields in adult glioblastoma patients with implanted non-programmable shunts, programmable shunts, and pacemakers/defibrillators: 6-year updated retrospective analysis